Use of thiazolidinediones for the treatment of hyperglycaemia
AssigneeSmithKline Beecham Corporation
InventorsRobin Edwin Buckingham, Stephen Alistair Smith
Life of this patent
Estimating the term…
Abstract
A method for the treatment of hyperglycaemia wherein plasma glucose levels are in the range of elevated normal to ≦126 mg/dl, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, to a mammal in need thereof.
Claims12
A method for the treatment of hyperglycaemia wherein plasma glucose levels are in the range of from elevated normal to ≦126 mg/dl, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, to a mammal in need thereof.
11 The use of an insulin sensitiser for the manufacture of a medicament for the treatment of hyperglycaemia wherein plasma glucose levels are in the range of from elevated normal to ≦126 mg/dl.
A pharmaceutical composition comprising an insulin sensitiser and a pharmaceutically acceptable carrier, for use in the treatment of hyperglycaemia wherein plasma glucose levels are in the range of from elevated normal to ≦126 mg/dl.
Dependencies are inferred from the claim text.